Synucleinopathies, a group of progressive neurological disorders that includes Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy, may have acquired a new molecular clue. In a study published in npj Parkinson’s Disease, Luan, Wei, Chen and colleagues report that proteomic analysis identified carboxypeptidase E, or CPE, as a potential biomarker for these disorders. The finding places an enzyme best known for its role in processing peptide hormones and neuropeptides at the center of a growing search for measurable biological signals that could reveal disease before severe, irreversible damage has occurred.
The importance of the discovery lies in the nature of synucleinopathies themselves. These diseases are defined in part by the abnormal accumulation and spread of misfolded alpha-synuclein, a protein involved in nerve-cell communication. Although alpha-synuclein pathology is a shared feature, patients can develop markedly different symptoms, rates of progression and patterns of brain involvement. Diagnosis is therefore often based on clinical examination, medical history and the gradual emergence of characteristic movement or cognitive symptoms. By the time these signs become unmistakable, substantial neuronal loss may already have taken place. A reliable molecular marker could help clinicians identify disease biology earlier and distinguish related disorders more precisely.
The researchers used proteomics, a technology that examines large collections of proteins in biological samples. Unlike conventional tests that focus on one molecule at a time, proteomic studies can compare thousands of proteins simultaneously, revealing changes in abundance, processing or chemical modification associated with disease. Such analyses are particularly valuable in neurodegeneration, where the relevant biological changes may involve interacting pathways rather than a single defective gene or protein. By surveying the protein landscape linked to synucleinopathies, the team identified CPE as a molecule worthy of further investigation as a diagnostic or disease-associated marker.
CPE is an enzyme that trims amino acids from the ends of specific protein and peptide precursors. In the nervous system, this processing activity helps generate biologically active neuropeptides, signaling molecules that influence stress responses, metabolism, pain, mood and other functions. The enzyme is found in secretory pathways inside cells, where it participates in the maturation of peptide hormones and neurotransmitter-related molecules. Its appearance in a proteomic signature of synucleinopathies is therefore biologically intriguing: changes in CPE could reflect disturbances in neuronal secretory machinery, altered peptide processing or broader cellular stress caused by accumulating alpha-synuclein.
The identification of CPE does not mean that the enzyme has been proven to cause Parkinson’s disease or any other synucleinopathy. A biomarker is a measurable feature associated with a disease, while a disease mechanism is a process that drives pathology. The distinction is essential. CPE might contribute directly to neuronal dysfunction, respond to damage occurring elsewhere in the cell or simply provide a sensitive readout of changes in vulnerable brain circuits. Establishing which explanation is correct will require additional work, including studies in larger patient groups, comparisons with other neurological conditions and experiments that alter CPE levels or activity in relevant cellular and animal models.
The potential clinical value of the finding will depend on how consistently CPE separates synucleinopathies from healthy aging and from disorders with overlapping symptoms. Parkinsonian movement problems can arise from several causes, and early disease may present with subtle tremor, slowness, changes in balance, sleep disturbances or loss of smell. A useful biomarker would ideally be detectable in an accessible sample such as blood or cerebrospinal fluid, perform reliably across laboratories and correlate with disease stage or progression. It would also need to complement, rather than replace, neurological examination and established imaging or laboratory approaches. The study’s contribution is to nominate CPE for that validation pathway.
Proteomics can also reveal why a candidate marker matters beyond its value as a diagnostic label. If CPE levels or molecular forms change in association with synuclein pathology, the signal could point investigators toward disrupted neuropeptide production, impaired vesicle trafficking or altered protein quality control. These systems are closely linked to the survival of dopamine-producing neurons, the cells most famously affected in Parkinson’s disease. Alpha-synuclein can interfere with membrane transport and vesicle release, while chronic cellular stress can reshape the proteins involved in secretion and degradation. CPE may consequently serve as a window into the biochemical consequences of these disturbances.
For patients and families, the most important question is whether a discovery such as this will accelerate treatment. The answer is not immediate, but biomarkers can transform the way therapies are developed. Clinical trials often enroll participants after symptoms are established, when the underlying pathology may be advanced and biologically diverse. A validated marker could help researchers recruit people with confirmed disease biology, divide participants into more meaningful subgroups and monitor whether an experimental treatment is affecting the intended process. If CPE changes in parallel with neuronal injury or therapeutic response, it might eventually help measure progression in ways that clinical rating scales alone cannot capture.
The report arrives during an intense international effort to move synucleinopathy research from symptom management toward molecular diagnosis and precision medicine. No single biomarker is likely to explain every form of Parkinson’s disease or related disorder, and CPE will face the same rigorous testing required of all promising candidates. Independent replication, standardized assays and long-term studies will determine whether the signal is robust, specific and clinically useful. For now, the proteomic identification of carboxypeptidase E adds a new piece to the puzzle of synuclein biology, offering researchers a technically measurable link between altered protein processing and the diseases that damage movement, cognition and the nervous system.
Subject of Research: Carboxypeptidase E as a potential biomarker for synucleinopathies, including Parkinson’s disease and related neurodegenerative disorders.
Article Title: Proteomics identified carboxypeptidase E as a novel biomarker for synucleinopathies.
Article References: Luan, M., Wei, L., Chen, J. et al. “Proteomics identified carboxypeptidase E as a novel biomarker for synucleinopathies.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01518-1
Image Credits: AI Generated
DOI: 10.1038/s41531-026-01518-1
Keywords: Synucleinopathies, Parkinson’s disease, carboxypeptidase E, CPE, proteomics, biomarkers, alpha-synuclein, neurodegeneration, Parkinson’s disease research
Tags: Advances in proteomics for neurological disordersBiological markers for early-stage neurodegenerationCarboxypeptidase E in neurodegenerative diseasesDistEarly detection biomarkers for synucleinopathiesEnzymes involved in peptide hormone processingMolecular signals in neurodegenerative disease diagnosisPotential biomarkers for multiple system atrophyProteomic analysis of Parkinson’s and Lewy body dementiaRole of alpha-synuclein in neurodegenerationSynucleinopathies biomarker discovery
